序贯内分泌治疗后延长辅助芳香化酶抑制治疗(DATA):随机3期试验
DATA研究为前瞻性、随机、开放标签、多中心3期试验,纳入79家荷兰医院绝经后激素受体阳性早期乳腺癌患者,在2-3年他莫昔芬辅助治疗后无复发迹象者随机接受3年或6年来曲唑治疗。6年组不良事件更多,包括全等级关节痛或肌痛和骨量减少或骨质疏松。
要点
- 绝经后激素受体阳性早期乳腺癌,2-3年他莫昔芬后随机接受3年或6年来曲唑。
- 6年组不良事件更多:全等级关节痛或肌痛58% vs 53%,骨量减少或骨质疏松21% vs 16%。
核心结论
- 不能推荐所有绝经后激素受体阳性乳腺癌患者在5年序贯内分泌治疗后使用延长辅助芳香化酶抑制治疗。
研究设计与样本
- DATA为前瞻性、随机、开放标签、多中心3期研究,在荷兰79家医院开展。
- 纳入绝经后激素受体阳性早期乳腺癌患者,在2-3年他莫昔芬辅助治疗后无复发迹象,按1:1随机分配至3年或6年来曲唑治疗(1 mg口服每日一次)。
- 随机化分层因素为淋巴结状态、激素受体状态、HER2状态和他莫昔芬治疗时长。
- 共筛查1912例患者,955例分配至3年组,957例分配至6年组;1860例符合条件(6年组931例,3年组929例),1660例在随机化3年后无病。
主要发现
- 6年治疗组不良事件多于3年治疗组,包括全等级关节痛或肌痛:6年组478/827(58%)vs 3年组438/833(53%)。
- 骨量减少或骨质疏松:6年组173/827(21%)vs 3年组137/833(16%)。
关键数值与推荐
- 来曲唑给药方案:1 mg口服每日一次。
- 主要终点为随机化3年后的 adapted 无病生存期。
临床怎么用
- 对于已完成5年序贯内分泌治疗(他莫昔芬后芳香化酶抑制剂)的绝经后激素受体阳性乳腺癌患者,不推荐普遍使用延长辅助芳香化酶抑制治疗。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The effect of extended adjuvant aromatase inhibition in hormone receptor-positive breast cancer after sequential endocrine therapy of tamoxifen followed by an aromatase inhibitor for a 5-year treatment period still needs clarification. To address this issue, we began the DATA study to assess different durations of anastrozole therapy after tamoxifen. METHODS: DATA was a prospective, randomised, open-label, multicentre, phase 3 study done in 79 hospitals in the Netherlands. We randomly assigned postmenopausal women with hormone receptor-positive early breast cancer with no signs of disease recurrence after 2-3 years of adjuvant tamoxifen to either 3 or 6 years of anastrozole treatment (1 mg orally once a day) in a 1:1 ratio. We used TENALEA (Trans European Network for Clinical Trials Services) for the randomisation procedure. Stratification factors were nodal status, hormone receptor status, HER2 status, and tamoxifen treatment duration. The primary study endpoint of this analysis was disease-free survival starting beyond 3 years after randomisation (adapted disease-free survival). Here we report the final analysis from the DATA trial, which is registered with ClinicalTrials.gov, number NCT00301457. FINDINGS: Between June 28, 2006, and Aug 10, 2009, we screened 1912 patients of whom 955 were assigned to the 3-year group and 957 to the 6-year anastrozole treatment group. 1860 patients were eligible (931 in the 6-year group and 929 in the 3-year group) and 1660 were disease free 3 years after randomisation. The 5-year adapted disease-free survival was 83·1% (95% CI 80·0-86·3) in the 6-year group and 79·4% (76·1-82·8) in the 3-year group (hazard ratio [HR] 0·79 [95% CI 0·62-1·02]; p=0·066). Patients in the 6-year treatment group had more adverse events than those in the 3-year treatment group, including all-grade arthralgia or myalgia (478 [58%] of 827 in the 6-year treatment group vs 438 [53%] of 833 in the 3-year treatment group) and osteopenia or osteoporosis (173 [21%] vs 137 [16%]). INTERPRETATION: We cannot recommend the use of extended adjuvant aromatase inhibition after 5 years of sequential endocrine therapy in all postmenopausal women with hormone receptor-positive breast cancer. FUNDING: AstraZeneca.
引用
- Tjan-Heijnen VCG, van Hellemond IEG, Peer PGM, et al. Extended adjuvant aromatase inhibition after sequential endocrine therapy (DATA): a randomised, phase 3 trial. Lancet Oncol. 2017. PMID: 29031778. doi:10.1016/S1470-2045(17)30600-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。